Replies to post #132 on Ligand Pharma Inc Roche Contingent Value Rights (LGNDZ)

[surf1944]

10:19AM Ligand Pharma partner GlaxoSmithKline (GSK) submits U.S. and European regulatory applications for use of Promacta/Revolade to increase platelet counts in patients with hepatitis C (LGND) 12.51 -0.15 : Co's partner GlaxoSmithKline (GSK) announced that it has submitted regulatory applications in the United States and European Union related to eltrombopag (Promacta/Revolade) and its use to increase platelet counts in patients with chronic hepatitis C virus infection and low platelets (thrombocytopenia), specifically: 1) A supplemental New Drug Application to the FDA for Promacta (eltrombopag) as a treatment for thrombocytopenia in adult patients with chronic hepatitis C infection to enable the initiation of interferon-based therapy and to optimize interferon-based therapy. 2) A variation to the Marketing Authorization Application to the European Medicines Agency for Revolade (eltrombopag) as a treatment for thrombocytopenia in adult patients with chronic hepatitis C infection to enable the initiation of interferon-based therapy and during interferon-based therapy.